17-PAAntagonist of neurosteroid potentiation and direct gating of GABAA CAS# 694438-95-4 |
- Alvespimycin
Catalog No.:BCC1346
CAS No.:467214-20-6
- 17-AAG (KOS953)
Catalog No.:BCC2121
CAS No.:75747-14-7
- Retaspimycin
Catalog No.:BCC1889
CAS No.:857402-23-4
- PU-H71
Catalog No.:BCC1872
CAS No.:873436-91-0
- 17-AAG Hydrochloride
Catalog No.:BCC1297
CAS No.:911710-03-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 694438-95-4 | SDF | Download SDF |
PubChem ID | 25068278 | Appearance | Powder |
Formula | C25H34O | M.Wt | 350.54 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 25 mM in DMSO and to 50 mM in ethanol | ||
Chemical Name | (3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-17-phenyl-2,3,4,5,6,7,8,9,11,12,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol | ||
SMILES | CC12CCC(CC1CCC3C2CCC4(C3CC=C4C5=CC=CC=C5)C)O | ||
Standard InChIKey | SINAMTXBCYKFDL-WBJZGETLSA-N | ||
Standard InChI | InChI=1S/C25H34O/c1-24-14-12-19(26)16-18(24)8-9-20-22-11-10-21(17-6-4-3-5-7-17)25(22,2)15-13-23(20)24/h3-7,10,18-20,22-23,26H,8-9,11-16H2,1-2H3/t18-,19+,20-,22-,23-,24-,25+/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Selective antagonist of neurosteroid potentiation and direct gating of GABAA receptors. Selectively reduces the effects of 5α-reduced steroids compared to 5β-reduced steroids and displays no effect on potentiation evoked by barbiturates and benzodiazepines. Attenuates 3α,5α-THP-induced loss of righting reflex and total sleep time following i.c.v administration in rats. |
17-PA Dilution Calculator
17-PA Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.8527 mL | 14.2637 mL | 28.5274 mL | 57.0548 mL | 71.3185 mL |
5 mM | 0.5705 mL | 2.8527 mL | 5.7055 mL | 11.411 mL | 14.2637 mL |
10 mM | 0.2853 mL | 1.4264 mL | 2.8527 mL | 5.7055 mL | 7.1319 mL |
50 mM | 0.0571 mL | 0.2853 mL | 0.5705 mL | 1.1411 mL | 1.4264 mL |
100 mM | 0.0285 mL | 0.1426 mL | 0.2853 mL | 0.5705 mL | 0.7132 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- SB505124
Catalog No.:BCC5087
CAS No.:694433-59-5
- Amonafide
Catalog No.:BCC1249
CAS No.:69408-81-7
- Lappaol H
Catalog No.:BCN8415
CAS No.:69394-18-9
- Sulbactam sodium
Catalog No.:BCC4852
CAS No.:69388-84-7
- Schisanhenol
Catalog No.:BCN2508
CAS No.:69363-14-0
- Pendulone
Catalog No.:BCN8248
CAS No.:69359-09-7
- Boc-D-Thr(Bzl)-OH
Catalog No.:BCC3454
CAS No.:69355-99-3
- Galanthamine hydrochloride
Catalog No.:BCC8277
CAS No.:5072-47-9
- Obtucarbamate A
Catalog No.:BCN3936
CAS No.:6935-99-5
- 2-Benzylaminopyridine
Catalog No.:BCC8565
CAS No.:6935-27-9
- CPPHA
Catalog No.:BCC1501
CAS No.:693288-97-0
- CYC116
Catalog No.:BCC2181
CAS No.:693228-63-6
- Parvifuran
Catalog No.:BCN7780
CAS No.:69470-93-5
- 2-Methyl-4-isobutyrylphloroglucinol
Catalog No.:BCN7176
CAS No.:69480-03-1
- Boc-D-His(Tos)-OH
Catalog No.:BCC3405
CAS No.:69541-68-0
- Thymopentin
Catalog No.:BCN8347
CAS No.:69558-55-0
- Octadecyl caffeate
Catalog No.:BCN6609
CAS No.:69573-60-0
- Tupichilignan A
Catalog No.:BCN4257
CAS No.:69586-96-5
- 4-Hydroxybenzylamine
Catalog No.:BCN1805
CAS No.:696-60-6
- CRT0044876
Catalog No.:BCC5109
CAS No.:6960-45-8
- Chamaejasmine
Catalog No.:BCN3132
CAS No.:69618-96-8
- H-D-Asp(OMe)-OMe.HCl
Catalog No.:BCC2897
CAS No.:69630-50-8
- H-D-Met-OMe.HCl
Catalog No.:BCC2998
CAS No.:69630-60-0
- Pd-C-II
Catalog No.:BCN4599
CAS No.:
Ethanol modulates the interaction of the endogenous neurosteroid allopregnanolone with the alpha1beta2gamma2L GABAA receptor.[Pubmed:17105870]
Mol Pharmacol. 2007 Feb;71(2):461-72.
We have examined alpha1beta2gamma2L GABAA receptor modulation by the endogenous steroids allopregnanolone (3alpha5alphaP), pregnenolone sulfate, and beta-estradiol in the absence and presence of ethanol. Coapplication of 0.1 to 1% (17-170 mM) ethanol influenced receptor modulation by 3alpha5alphaP but not that by pregnenolone sulfate or beta-estradiol. One of the three kinetic effects evident in channel potentiation by 3alpha5alphaP, prolongation of the longest-lived open time component (OT3), was affected by ethanol with the midpoint of its dose-response curve moved to lower steroid concentrations by 2 orders of magnitude without significantly affecting the maximal effect. Manipulations designed to affect the ability of 3alpha5alphaP to prolong OT3 also affected OT3 prolongation in the presence of ethanol. A mutation to the gamma2 subunit, which reduces the ability of 3alpha5alphaP to prolong OT3, also reduces the interaction between ethanol and 3alpha5alphaP. And the presence of the competitive steroid antagonist (3alpha,5alpha)-17-phenylandrost-16-en-3-ol (17-PA) diminishes the positive interaction between ethanol and 3alpha5alphaP on the GABAA receptor. Together, the findings suggest that steroid interactions with the classic steroid binding site underlie the effect seen in the presence of ethanol, and that ethanol acts by increasing the affinity of 3alpha5alphaP for the site. Tadpole behavioral assays showed that the presence of 3alpha5alphaP at a concentration ineffective at causing changes in tadpole behavior shifted the ethanol dose-response curve for loss of righting reflex to lower concentrations and that this effect was neutralized by coapplication of 17-PA with 3alpha5alphaP.
Antagonism of neurosteroid modulation of native gamma-aminobutyric acid receptors by (3alpha,5alpha)-17-phenylandrost-16-en-3-ol.[Pubmed:17658511]
Eur J Pharmacol. 2007 Oct 31;572(2-3):94-101.
Endogenous pregnane neurosteroids are allosteric modulators at gamma-aminobutyric acid type-A (GABAA) receptors at nanomolar concentrations. There is direct evidence for multiple distinct neurosteroid binding sites on GABAA receptors, dependent upon subunit composition and stoichiometry. This view is supported by the biphasic kinetics of various neuroactive steroids, enantioselectivity of some neurosteroids, selective mutation studies of recombinantly expressed receptors and the selectivity of the neurosteroid antagonist (3alpha,5alpha)-17-phenylandrost-16-en-3-ol (17PA) on 5alpha-pregnane steroid effects on recombinant GABAA receptors expressed in Xenopus oocytes and native receptors in dissociated neurons. However, it is unclear whether this antagonist action is present in a mature mammalian system. The present study evaluated the antagonist activity of 17PA on neurosteroid agonists both in vivo and in vitro by examining the effects of 17PA on 5alpha-pregnane-induced sedation in rats, native mature GABAA receptor ion channels utilizing the chloride flux assay and further studies in recombinant alpha1beta2gamma2 receptors. The data show that 17PA preferentially inhibits 3alpha,5alpha-THP vs. alphaxalone in vivo, preferentially inhibits 3alpha,5alpha-THDOC vs. alphaxalone potentiation of GABA-mediated Cl- uptake in adult cerebral cortical synaptoneurosomes, but shows no specificity for 3alpha,5alpha-THDOC vs. alphaxalone in recombinant alpha1beta2gamma2 receptors. These data provide further evidence of the specificity of 17PA and the heterogeneity of neurosteroid recognition sites on GABAA receptors in the CNS.
Selective antagonism of 5alpha-reduced neurosteroid effects at GABA(A) receptors.[Pubmed:15102947]
Mol Pharmacol. 2004 May;65(5):1191-7.
Although neurosteroids have rapid effects on GABA(A) receptors, study of steroid actions at GABA receptors has been hampered by a lack of pharmacological antagonists. In this study, we report the synthesis and characterization of a steroid analog, (3alpha,5alpha)-17-phenylandrost-16-en-3-ol (17PA), that selectively antagonized neurosteroid potentiation of GABA responses. We examined 17PA using the alpha1beta2gamma2 subunit combination expressed in Xenopus laevis oocytes. 17PA had little or no effect on baseline GABA responses but antagonized both the response augmentation and the direct gating of GABA receptors by 5alpha-reduced potentiating steroids. The effect was selective for 5alpha-reduced potentiating steroids; 5beta-reduced potentiators were only weakly affected. Likewise, 17PA did not affect barbiturate and benzodiazepine potentiation. 17PA acted primarily by shifting the concentration response for steroid potentiation to the right, suggesting the possibility of a competitive component to the antagonism. 17PA also antagonized 5alpha-reduced steroid potentiation and gating in hippocampal neurons and inhibited anesthetic actions in X. laevis tadpoles. Analogous to benzodiazepine site antagonists, the development of neurosteroid antagonists may help clarify the role of GABA-potentiating neurosteroids in health and disease.